Literature DB >> 34583959

EHR-Integrated Monitor Data to Measure Pulse Oximetry Use in Bronchiolitis.

Andrew S Kern-Goldberger1, Irit R Rasooly2,3,4,5, Brooke Luo2,3,5, Sansanee Craig2,3,5, Daria F Ferro2,3,5, Halley Ruppel4,6, Padmavathy Parthasarathy2,5, Nathaniel Sergay2,7, Courtney M Solomon8,9, Kate E Lucey10,11, Naveen Muthu2,3,4,5, Christopher P Bonafide.   

Abstract

BACKGROUND AND OBJECTIVES: Continuous pulse oximetry (oxygen saturation [Spo2]) monitoring in hospitalized children with bronchiolitis not requiring supplemental oxygen is discouraged by national guidelines, but determining monitoring status accurately requires in-person observation. Our objective was to determine if electronic health record (EHR) data can accurately estimate the extent of actual Spo2 monitoring use in bronchiolitis.
METHODS: This repeated cross-sectional study included infants aged 8 weeks through 23 months hospitalized with bronchiolitis. In the validation phase at 3 children's hospitals, we calculated the test characteristics of the Spo2 monitor data streamed into the EHR each minute when monitoring was active compared with in-person observation of Spo2 monitoring use. In the application phase at 1 children's hospital, we identified periods when supplemental oxygen was administered using EHR flowsheet documentation and calculated the duration of Spo2 monitoring that occurred in the absence of supplemental oxygen.
RESULTS: Among 668 infants at 3 hospitals (validation phase), EHR-integrated Spo2 data from the same minute as in-person observation had a sensitivity of 90%, specificity of 98%, positive predictive value of 88%, and negative predictive value of 98% for actual Spo2 monitoring use. Using EHR-integrated data in a sample of 317 infants at 1 hospital (application phase), infants were monitored in the absence of oxygen supplementation for a median 4.1 hours (interquartile range 1.4-9.4 hours). Those who received supplemental oxygen experienced a median 5.6 hours (interquartile range 3.0-10.6 hours) of monitoring after oxygen was stopped.
CONCLUSIONS: EHR-integrated monitor data are a valid measure of actual Spo2 monitoring use that may help hospitals more efficiently identify opportunities to deimplement guideline-inconsistent use.
Copyright © 2021 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34583959      PMCID: PMC8487905          DOI: 10.1542/hpeds.2021-005894

Source DB:  PubMed          Journal:  Hosp Pediatr        ISSN: 2154-1671


  26 in total

1.  Association between exposure to nonactionable physiologic monitor alarms and response time in a children's hospital.

Authors:  Christopher P Bonafide; Richard Lin; Miriam Zander; Christian Sarkis Graham; Christine W Paine; Whitney Rock; Andrew Rich; Kathryn E Roberts; Margaret Fortino; Vinay M Nadkarni; A Russell Localio; Ron Keren
Journal:  J Hosp Med       Date:  2015-04-15       Impact factor: 2.960

Review 2.  The US Office of the National Coordinator for Health Information Technology: Progress and Promise for the Future at the 10-Year Mark.

Authors:  Karen B DeSalvo; Ayame Nagatani Dinkler; Lee Stevens
Journal:  Ann Emerg Med       Date:  2015-05-09       Impact factor: 5.721

3.  The frequency of physiologic monitor alarms in a children's hospital.

Authors:  Amanda C Schondelmeyer; Christopher P Bonafide; Veena V Goel; Nancy Blake; Maria Cvach; Heidi Sucharew; Jeffrey M Simmons; Patrick W Brady
Journal:  J Hosp Med       Date:  2016-05-28       Impact factor: 2.960

4.  Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis.

Authors:  Shawn L Ralston; Allan S Lieberthal; H Cody Meissner; Brian K Alverson; Jill E Baley; Anne M Gadomski; David W Johnson; Michael J Light; Nizar F Maraqa; Eneida A Mendonca; Kieran J Phelan; Joseph J Zorc; Danette Stanko-Lopp; Mark A Brown; Ian Nathanson; Elizabeth Rosenblum; Stephen Sayles; Sinsi Hernandez-Cancio
Journal:  Pediatrics       Date:  2014-11       Impact factor: 7.124

5.  Overuse of Continuous Pulse Oximetry for Bronchiolitis: The Need for Deimplementation Science.

Authors:  Christine C Cheston; Robert J Vinci
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

Review 6.  Choosing wisely in pediatric hospital medicine: five opportunities for improved healthcare value.

Authors:  Ricardo A Quinonez; Matthew D Garber; Alan R Schroeder; Brian K Alverson; Wendy Nickel; Jenna Goldstein; Jeffrey S Bennett; Bryan R Fine; Timothy H Hartzog; Heather S McLean; Vineeta Mittal; Rita M Pappas; Jack M Percelay; Shannon C Phillips; Mark Shen; Shawn L Ralston
Journal:  J Hosp Med       Date:  2013-08-19       Impact factor: 2.960

7.  A Multicenter Collaborative to Reduce Unnecessary Care in Inpatient Bronchiolitis.

Authors:  Shawn L Ralston; Matthew D Garber; Elizabeth Rice-Conboy; Grant M Mussman; Kristin A Shadman; Susan C Walley; Elizabeth Nichols
Journal:  Pediatrics       Date:  2015-12-01       Impact factor: 7.124

8.  Progress In Interoperability: Measuring US Hospitals' Engagement In Sharing Patient Data.

Authors:  A Jay Holmgren; Vaishali Patel; Julia Adler-Milstein
Journal:  Health Aff (Millwood)       Date:  2017-10-01       Impact factor: 6.301

9.  Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices.

Authors:  Vinay Prasad; John Pa Ioannidis
Journal:  Implement Sci       Date:  2014-01-08       Impact factor: 7.327

10.  Measuring overuse of continuous pulse oximetry in bronchiolitis and developing strategies for large-scale deimplementation: study protocol for a feasibility trial.

Authors:  Irit R Rasooly; Rinad S Beidas; Courtney Benjamin Wolk; Frances Barg; Christopher P Landrigan; Amanda Schondelmeyer; Patrick W Brady; Lisa M McLeod; Christopher P Bonafide
Journal:  Pilot Feasibility Stud       Date:  2019-05-15
View more
  1 in total

1.  The Alarm Burden of Excess Continuous Pulse Oximetry Monitoring Among Patients With Bronchiolitis.

Authors:  Irit R Rasooly; Spandana Makeneni; Amina N Khan; Brooke Luo; Naveen Muthu; Christopher P Bonafide
Journal:  J Hosp Med       Date:  2021-12       Impact factor: 2.960

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.